Anti-B7S1 polypeptides and their use
US12358985B2 · kind B2 · utility
0Cited by
0References
17Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 23, 2020 |
| Grant date | Jul 15, 2025 |
| Priority date | — |
| Expiry date | Jan 27, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is related to anti-B7S1 (B7-H4) polypeptides including anti-B7S1 (B7-H4) antibodies and their immunoreactive fragments, chimeric antigen receptor (CAR) binding to B7S1 (B7-H4) molecule and the uses thereof, particularly in the treatment of cancers. The invention particularly concerns humanized anti-B7S1 antibodies and their antigen binding fragments capable of enhancing the activation of the immune system against diseased tissues including cancerous cells, and the genetically engineered immune cells expressing anti-B7S1 CAR used for treatment of diseases including cancers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.